SERTRALINE HCL
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (N06A, N06AB) — coverage varies; not interchangeable
- Citalopram (Celexa): general benefit, Not a benefit
- Escitalopram (Cipralex MELTZ): general benefit, Not a benefit
- Fluoxetine (Prozac): general benefit, Not a benefit
- Fluvoxamine (Luvox): general benefit
- Paroxetine (Paxil): general benefit, Not a benefit
- Amitriptyline (Elavil): general benefit
17 more in the class list below
AG-Sertraline · DIN 02477882 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Sertraline · DIN 02477882
Manufacturer: Angita Pharma Inc.; listing date 2020-12-18
Health Canada: Marketed since 2018-09-06 · brand AG-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Angita pharma inc. · schedule Prescription
AG-Sertraline: Formulary list price $0.1516/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96809 · Verify on the e-Formulary ↗ (DIN 02477882)
Source record
DIN 02477882: AG-Sertraline
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id ANG
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1516; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02477882
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96809
Interchangeable products
Apo-Sertraline · DIN 02238280 · $0.1516
Auro-Sertraline · DIN 02390906 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
M-Sertraline · DIN 02530937 · $0.1516
Mar-Sertraline · DIN 02399415 · $0.1516
Mint-Sertraline · DIN 02402378 · $0.1516
NRA-Sertraline · DIN 02488434 · $0.1516
PMS-Sertraline · DIN 02244838 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02353520 · $0.1516
Sertraline · DIN 02386070 · $0.1516
Sertraline · DIN 02469626 · $0.1516
Teva-Sertraline · DIN 02240485 · $0.1516
Zoloft · DIN 02132702 · $0.1516
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02477882
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Sertraline · DIN 02238280 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sertraline · DIN 02238280
Manufacturer: Apotex Inc.; listing date 2000-01-17
Health Canada: Marketed since 1999-09-01 · brand APO-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Apotex inc · schedule Prescription
Apo-Sertraline: Formulary list price $0.1516/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61676 · Verify on the e-Formulary ↗ (DIN 02238280)
Source record
DIN 02238280: Apo-Sertraline
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id APX
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1516; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238280
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61676
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516
Auro-Sertraline · DIN 02390906 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
M-Sertraline · DIN 02530937 · $0.1516
Mar-Sertraline · DIN 02399415 · $0.1516
Mint-Sertraline · DIN 02402378 · $0.1516
NRA-Sertraline · DIN 02488434 · $0.1516
PMS-Sertraline · DIN 02244838 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02353520 · $0.1516
Sertraline · DIN 02386070 · $0.1516
Sertraline · DIN 02469626 · $0.1516
Teva-Sertraline · DIN 02240485 · $0.1516
Zoloft · DIN 02132702 · $0.1516
Shortage status: resolved shortage (ended 2024-10-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238280
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Sertraline · DIN 02390906 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Sertraline · DIN 02390906
Manufacturer: Auro Pharma Inc.; listing date 2012-12-21
Health Canada: Marketed since 2012-10-18 · brand AURO-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Auro pharma inc · schedule Prescription
Auro-Sertraline: Formulary list price $0.1516/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87629 · Verify on the e-Formulary ↗ (DIN 02390906)
Source record
DIN 02390906: Auro-Sertraline
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id AUR
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1516; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390906
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87629
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516
Apo-Sertraline · DIN 02238280 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
M-Sertraline · DIN 02530937 · $0.1516
Mar-Sertraline · DIN 02399415 · $0.1516
Mint-Sertraline · DIN 02402378 · $0.1516
NRA-Sertraline · DIN 02488434 · $0.1516
PMS-Sertraline · DIN 02244838 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02353520 · $0.1516
Sertraline · DIN 02386070 · $0.1516
Sertraline · DIN 02469626 · $0.1516
Teva-Sertraline · DIN 02240485 · $0.1516
Zoloft · DIN 02132702 · $0.1516
Shortage status: resolved shortage (ended 2024-04-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02390906
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Sertraline · DIN 02530937 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Sertraline · DIN 02530937
Manufacturer: Mantra Pharma Inc.; listing date 2023-04-28
Health Canada: Marketed since 2023-03-20 · brand M-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Mantra pharma inc · schedule Prescription
M-Sertraline: Formulary list price $0.1516/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102010 · Verify on the e-Formulary ↗ (DIN 02530937)
Source record
DIN 02530937: M-Sertraline
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id MAT
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1516; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02530937
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102010
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516
Apo-Sertraline · DIN 02238280 · $0.1516
Auro-Sertraline · DIN 02390906 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
Mar-Sertraline · DIN 02399415 · $0.1516
Mint-Sertraline · DIN 02402378 · $0.1516
NRA-Sertraline · DIN 02488434 · $0.1516
PMS-Sertraline · DIN 02244838 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02353520 · $0.1516
Sertraline · DIN 02386070 · $0.1516
Sertraline · DIN 02469626 · $0.1516
Teva-Sertraline · DIN 02240485 · $0.1516
Zoloft · DIN 02132702 · $0.1516
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02530937
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Sertraline · DIN 02399415 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Sertraline · DIN 02399415
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2013-03-20
Health Canada: Marketed since 2014-01-16 · brand MAR-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Sertraline: Formulary list price $0.1516/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88430 · Verify on the e-Formulary ↗ (DIN 02399415)
Source record
DIN 02399415: Mar-Sertraline
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id MAR
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1516; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02399415
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88430
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516
Apo-Sertraline · DIN 02238280 · $0.1516
Auro-Sertraline · DIN 02390906 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
M-Sertraline · DIN 02530937 · $0.1516
Mint-Sertraline · DIN 02402378 · $0.1516
NRA-Sertraline · DIN 02488434 · $0.1516
PMS-Sertraline · DIN 02244838 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02353520 · $0.1516
Sertraline · DIN 02386070 · $0.1516
Sertraline · DIN 02469626 · $0.1516
Teva-Sertraline · DIN 02240485 · $0.1516
Zoloft · DIN 02132702 · $0.1516
Shortage status: resolved shortage (ended 2018-12-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02399415
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Sertraline · DIN 02402378 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Sertraline · DIN 02402378
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-06-27
Health Canada: Marketed since 2013-04-29 · brand MINT-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Sertraline: Formulary list price $0.1516/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88721 · Verify on the e-Formulary ↗ (DIN 02402378)
Source record
DIN 02402378: Mint-Sertraline
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id MIN
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1516; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02402378
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88721
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516
Apo-Sertraline · DIN 02238280 · $0.1516
Auro-Sertraline · DIN 02390906 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
M-Sertraline · DIN 02530937 · $0.1516
Mar-Sertraline · DIN 02399415 · $0.1516
NRA-Sertraline · DIN 02488434 · $0.1516
PMS-Sertraline · DIN 02244838 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02353520 · $0.1516
Sertraline · DIN 02386070 · $0.1516
Sertraline · DIN 02469626 · $0.1516
Teva-Sertraline · DIN 02240485 · $0.1516
Zoloft · DIN 02132702 · $0.1516
Shortage status: resolved shortage (ended 2018-03-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02402378
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Sertraline · DIN 02488434 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Sertraline · DIN 02488434
Manufacturer: Nora Pharma; listing date 2021-03-29
Health Canada: Marketed since 2019-09-04 · brand NRA-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Nora pharma inc · schedule Prescription
NRA-Sertraline: Formulary list price $0.1516/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97852 · Verify on the e-Formulary ↗ (DIN 02488434)
Source record
DIN 02488434: NRA-Sertraline
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id NRA
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1516; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02488434
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97852
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516
Apo-Sertraline · DIN 02238280 · $0.1516
Auro-Sertraline · DIN 02390906 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
M-Sertraline · DIN 02530937 · $0.1516
Mar-Sertraline · DIN 02399415 · $0.1516
Mint-Sertraline · DIN 02402378 · $0.1516
PMS-Sertraline · DIN 02244838 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02353520 · $0.1516
Sertraline · DIN 02386070 · $0.1516
Sertraline · DIN 02469626 · $0.1516
Teva-Sertraline · DIN 02240485 · $0.1516
Zoloft · DIN 02132702 · $0.1516
Shortage status: resolved shortage (ended 2020-12-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02488434
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Sertraline · DIN 02244838 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Sertraline · DIN 02244838
Manufacturer: Pharmascience Inc.; listing date 2003-01-30
Health Canada: Marketed since 2002-01-30 · brand PMS-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Pharmascience inc · schedule Prescription
PMS-Sertraline: Formulary list price $0.1516/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68828 · Verify on the e-Formulary ↗ (DIN 02244838)
Source record
DIN 02244838: PMS-Sertraline
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id PMS
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1516; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244838
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68828
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516
Apo-Sertraline · DIN 02238280 · $0.1516
Auro-Sertraline · DIN 02390906 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
M-Sertraline · DIN 02530937 · $0.1516
Mar-Sertraline · DIN 02399415 · $0.1516
Mint-Sertraline · DIN 02402378 · $0.1516
NRA-Sertraline · DIN 02488434 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02353520 · $0.1516
Sertraline · DIN 02386070 · $0.1516
Sertraline · DIN 02469626 · $0.1516
Teva-Sertraline · DIN 02240485 · $0.1516
Zoloft · DIN 02132702 · $0.1516
Shortage status: resolved shortage (ended 2018-04-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244838
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sertraline · DIN 02353520 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sertraline · DIN 02353520
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2022-06-21 · brand SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Sanis health inc · schedule Prescription
Sertraline: Formulary list price $0.1516/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83874 · Verify on the e-Formulary ↗ (DIN 02353520)
Source record
DIN 02353520: Sertraline
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id SAI
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1516; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02353520
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83874
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516
Apo-Sertraline · DIN 02238280 · $0.1516
Auro-Sertraline · DIN 02390906 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
M-Sertraline · DIN 02530937 · $0.1516
Mar-Sertraline · DIN 02399415 · $0.1516
Mint-Sertraline · DIN 02402378 · $0.1516
NRA-Sertraline · DIN 02488434 · $0.1516
PMS-Sertraline · DIN 02244838 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02386070 · $0.1516
Sertraline · DIN 02469626 · $0.1516
Teva-Sertraline · DIN 02240485 · $0.1516
Zoloft · DIN 02132702 · $0.1516
Shortage status: resolved shortage (ended 2026-03-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02353520
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sertraline · DIN 02386070 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sertraline · DIN 02386070
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2019-04-05 · brand SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Sertraline: Formulary list price $0.1516/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87166 · Verify on the e-Formulary ↗ (DIN 02386070)
Source record
DIN 02386070: Sertraline
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id SIV
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1516; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386070
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87166
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516
Apo-Sertraline · DIN 02238280 · $0.1516
Auro-Sertraline · DIN 02390906 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
M-Sertraline · DIN 02530937 · $0.1516
Mar-Sertraline · DIN 02399415 · $0.1516
Mint-Sertraline · DIN 02402378 · $0.1516
NRA-Sertraline · DIN 02488434 · $0.1516
PMS-Sertraline · DIN 02244838 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02353520 · $0.1516
Sertraline · DIN 02469626 · $0.1516
Teva-Sertraline · DIN 02240485 · $0.1516
Zoloft · DIN 02132702 · $0.1516
Shortage status: resolved shortage (ended 2019-04-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02386070
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sertraline · DIN 02469626 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sertraline · DIN 02469626
Manufacturer: Jamp Pharma Corporation; listing date 2018-02-28
Health Canada: Marketed since 2018-01-17 · brand SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Jamp pharma corporation · schedule Prescription
Sertraline: Formulary list price $0.1516/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95842 · Verify on the e-Formulary ↗ (DIN 02469626)
Source record
DIN 02469626: Sertraline
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id JPC
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1516; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02469626
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95842
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516
Apo-Sertraline · DIN 02238280 · $0.1516
Auro-Sertraline · DIN 02390906 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
M-Sertraline · DIN 02530937 · $0.1516
Mar-Sertraline · DIN 02399415 · $0.1516
Mint-Sertraline · DIN 02402378 · $0.1516
NRA-Sertraline · DIN 02488434 · $0.1516
PMS-Sertraline · DIN 02244838 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02353520 · $0.1516
Sertraline · DIN 02386070 · $0.1516
Teva-Sertraline · DIN 02240485 · $0.1516
Zoloft · DIN 02132702 · $0.1516
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02469626
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Sertraline · DIN 02240485 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Sertraline · DIN 02240485
Manufacturer: Teva Canada Limited; listing date 2000-01-17
Health Canada: Marketed since 2010-11-13 · brand TEVA-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Teva canada limited · schedule Prescription
Teva-Sertraline: Formulary list price $0.1516/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64055 · Verify on the e-Formulary ↗ (DIN 02240485)
Source record
DIN 02240485: Teva-Sertraline
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id TEV
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1516; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240485
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64055
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516
Apo-Sertraline · DIN 02238280 · $0.1516
Auro-Sertraline · DIN 02390906 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
M-Sertraline · DIN 02530937 · $0.1516
Mar-Sertraline · DIN 02399415 · $0.1516
Mint-Sertraline · DIN 02402378 · $0.1516
NRA-Sertraline · DIN 02488434 · $0.1516
PMS-Sertraline · DIN 02244838 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02353520 · $0.1516
Sertraline · DIN 02386070 · $0.1516
Sertraline · DIN 02469626 · $0.1516
Zoloft · DIN 02132702 · $0.1516
Shortage status: resolved shortage (ended 2026-01-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02240485
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Zoloft · DIN 02132702 · 25mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Zoloft (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Zoloft · DIN 02132702
Manufacturer: Upjohn Canada ULC; listing date 1996-10-01
Health Canada: Marketed since 2023-08-22 · brand ZOLOFT · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 25 MG · company Bgp pharma ulc · schedule Prescription
Ministry pays: $0.1516 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18005 · Verify on the e-Formulary ↗ (DIN 02132702)
Source record
DIN 02132702: Zoloft
Raw flags: sec3=Y
Item: 281604093; group id 470; item number 1181; lccId None; manufacturer id UJC
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $1.0460; ministry $0.1516
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02132702
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18005
Interchangeable products
AG-Sertraline · DIN 02477882 · $0.1516
Apo-Sertraline · DIN 02238280 · $0.1516
Auro-Sertraline · DIN 02390906 · $0.1516
Co Sertraline · DIN 02287390 · $0.1516
Jamp-Sertraline · DIN 02357143 · $0.1516
M-Sertraline · DIN 02530937 · $0.1516
Mar-Sertraline · DIN 02399415 · $0.1516
Mint-Sertraline · DIN 02402378 · $0.1516
NRA-Sertraline · DIN 02488434 · $0.1516
PMS-Sertraline · DIN 02244838 · $0.1516
Sandoz Sertraline · DIN 02245159 · $0.1516
Sertraline · DIN 02353520 · $0.1516
Sertraline · DIN 02386070 · $0.1516
Sertraline · DIN 02469626 · $0.1516
Teva-Sertraline · DIN 02240485 · $0.1516
Shortage status: anticipated shortage (last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02132702
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AG-Sertraline · DIN 02477890 · 50mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Sertraline · DIN 02477890
Manufacturer: Angita Pharma Inc.; listing date 2020-12-18
Health Canada: Marketed since 2018-09-06 · brand AG-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 50 MG · company Angita pharma inc. · schedule Prescription
AG-Sertraline: Formulary list price $0.3032/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3032 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96810 · Verify on the e-Formulary ↗ (DIN 02477890)
Source record
DIN 02477890: AG-Sertraline
Raw flags: sec3=Y
Item: 281604060; group id 470; item number 1182; lccId None; manufacturer id ANG
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.3032; ministry $0.3032
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02477890
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96810
Interchangeable products
Apo-Sertraline · DIN 02238281 · $0.3032
Auro-Sertraline · DIN 02390914 · $0.3032
Co Sertraline · DIN 02287404 · $0.3032
Jamp-Sertraline · DIN 02357151 · $0.3032
M-Sertraline · DIN 02530945 · $0.3032
Mar-Sertraline · DIN 02399423 · $0.3032
Mint-Sertraline · DIN 02402394 · $0.3032
NRA-Sertraline · DIN 02488442 · $0.3032
PMS-Sertraline · DIN 02244839 · $0.3032
Sandoz Sertraline · DIN 02245160 · $0.3032
Sertraline · DIN 02353539 · $0.3032
Sertraline · DIN 02386089 · $0.3032
Sertraline · DIN 02469634 · $0.3032
Teva-Sertraline · DIN 02240484 · $0.3032
Zoloft · DIN 01962817 · $0.3032
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02477890
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Sertraline · DIN 02238281 · 50mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sertraline · DIN 02238281
Manufacturer: Apotex Inc.; listing date 2000-01-17
Health Canada: Marketed since 1999-09-01 · brand APO-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 50 MG · company Apotex inc · schedule Prescription
Apo-Sertraline: Formulary list price $0.3032/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3032 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61677 · Verify on the e-Formulary ↗ (DIN 02238281)
Source record
DIN 02238281: Apo-Sertraline
Raw flags: sec3=Y
Item: 281604060; group id 470; item number 1182; lccId None; manufacturer id APX
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.3032; ministry $0.3032
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238281
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61677
Interchangeable products
AG-Sertraline · DIN 02477890 · $0.3032
Auro-Sertraline · DIN 02390914 · $0.3032
Co Sertraline · DIN 02287404 · $0.3032
Jamp-Sertraline · DIN 02357151 · $0.3032
M-Sertraline · DIN 02530945 · $0.3032
Mar-Sertraline · DIN 02399423 · $0.3032
Mint-Sertraline · DIN 02402394 · $0.3032
NRA-Sertraline · DIN 02488442 · $0.3032
PMS-Sertraline · DIN 02244839 · $0.3032
Sandoz Sertraline · DIN 02245160 · $0.3032
Sertraline · DIN 02353539 · $0.3032
Sertraline · DIN 02386089 · $0.3032
Sertraline · DIN 02469634 · $0.3032
Teva-Sertraline · DIN 02240484 · $0.3032
Zoloft · DIN 01962817 · $0.3032
Shortage status: resolved shortage (ended 2024-10-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238281
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Sertraline · DIN 02390914 · 50mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Sertraline · DIN 02390914
Manufacturer: Auro Pharma Inc.; listing date 2012-12-21
Health Canada: Marketed since 2012-10-18 · brand AURO-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 50 MG · company Auro pharma inc · schedule Prescription
Auro-Sertraline: Formulary list price $0.3032/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3032 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87630 · Verify on the e-Formulary ↗ (DIN 02390914)
Source record
DIN 02390914: Auro-Sertraline
Raw flags: sec3=Y
Item: 281604060; group id 470; item number 1182; lccId None; manufacturer id AUR
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.3032; ministry $0.3032
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390914
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87630
Interchangeable products
AG-Sertraline · DIN 02477890 · $0.3032
Apo-Sertraline · DIN 02238281 · $0.3032
Co Sertraline · DIN 02287404 · $0.3032
Jamp-Sertraline · DIN 02357151 · $0.3032
M-Sertraline · DIN 02530945 · $0.3032
Mar-Sertraline · DIN 02399423 · $0.3032
Mint-Sertraline · DIN 02402394 · $0.3032
NRA-Sertraline · DIN 02488442 · $0.3032
PMS-Sertraline · DIN 02244839 · $0.3032
Sandoz Sertraline · DIN 02245160 · $0.3032
Sertraline · DIN 02353539 · $0.3032
Sertraline · DIN 02386089 · $0.3032
Sertraline · DIN 02469634 · $0.3032
Teva-Sertraline · DIN 02240484 · $0.3032
Zoloft · DIN 01962817 · $0.3032
Shortage status: resolved shortage (ended 2024-04-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02390914
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Sertraline · DIN 02530945 · 50mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Sertraline · DIN 02530945
Manufacturer: Mantra Pharma Inc.; listing date 2023-04-28
Health Canada: Marketed since 2023-03-20 · brand M-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 50 MG · company Mantra pharma inc · schedule Prescription
M-Sertraline: Formulary list price $0.3032/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3032 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102011 · Verify on the e-Formulary ↗ (DIN 02530945)
Source record
DIN 02530945: M-Sertraline
Raw flags: sec3=Y
Item: 281604060; group id 470; item number 1182; lccId None; manufacturer id MAT
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.3032; ministry $0.3032
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02530945
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102011
Interchangeable products
AG-Sertraline · DIN 02477890 · $0.3032
Apo-Sertraline · DIN 02238281 · $0.3032
Auro-Sertraline · DIN 02390914 · $0.3032
Co Sertraline · DIN 02287404 · $0.3032
Jamp-Sertraline · DIN 02357151 · $0.3032
Mar-Sertraline · DIN 02399423 · $0.3032
Mint-Sertraline · DIN 02402394 · $0.3032
NRA-Sertraline · DIN 02488442 · $0.3032
PMS-Sertraline · DIN 02244839 · $0.3032
Sandoz Sertraline · DIN 02245160 · $0.3032
Sertraline · DIN 02353539 · $0.3032
Sertraline · DIN 02386089 · $0.3032
Sertraline · DIN 02469634 · $0.3032
Teva-Sertraline · DIN 02240484 · $0.3032
Zoloft · DIN 01962817 · $0.3032
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02530945
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Sertraline · DIN 02399423 · 50mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Sertraline · DIN 02399423
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2013-03-20
Health Canada: Marketed since 2014-01-06 · brand MAR-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 50 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Sertraline: Formulary list price $0.3032/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3032 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88431 · Verify on the e-Formulary ↗ (DIN 02399423)
Source record
DIN 02399423: Mar-Sertraline
Raw flags: sec3=Y
Item: 281604060; group id 470; item number 1182; lccId None; manufacturer id MAR
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.3032; ministry $0.3032
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02399423
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88431
Interchangeable products
AG-Sertraline · DIN 02477890 · $0.3032
Apo-Sertraline · DIN 02238281 · $0.3032
Auro-Sertraline · DIN 02390914 · $0.3032
Co Sertraline · DIN 02287404 · $0.3032
Jamp-Sertraline · DIN 02357151 · $0.3032
M-Sertraline · DIN 02530945 · $0.3032
Mint-Sertraline · DIN 02402394 · $0.3032
NRA-Sertraline · DIN 02488442 · $0.3032
PMS-Sertraline · DIN 02244839 · $0.3032
Sandoz Sertraline · DIN 02245160 · $0.3032
Sertraline · DIN 02353539 · $0.3032
Sertraline · DIN 02386089 · $0.3032
Sertraline · DIN 02469634 · $0.3032
Teva-Sertraline · DIN 02240484 · $0.3032
Zoloft · DIN 01962817 · $0.3032
Shortage status: discontinued (2018-01-24, reported by MARCAN PHARMACEUTICALS INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02399423
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Sertraline · DIN 02402394 · 50mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Sertraline · DIN 02402394
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-06-27
Health Canada: Marketed since 2013-04-29 · brand MINT-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 50 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Sertraline: Formulary list price $0.3032/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3032 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88722 · Verify on the e-Formulary ↗ (DIN 02402394)
Source record
DIN 02402394: Mint-Sertraline
Raw flags: sec3=Y
Item: 281604060; group id 470; item number 1182; lccId None; manufacturer id MIN
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.3032; ministry $0.3032
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02402394
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88722
Interchangeable products
AG-Sertraline · DIN 02477890 · $0.3032
Apo-Sertraline · DIN 02238281 · $0.3032
Auro-Sertraline · DIN 02390914 · $0.3032
Co Sertraline · DIN 02287404 · $0.3032
Jamp-Sertraline · DIN 02357151 · $0.3032
M-Sertraline · DIN 02530945 · $0.3032
Mar-Sertraline · DIN 02399423 · $0.3032
NRA-Sertraline · DIN 02488442 · $0.3032
PMS-Sertraline · DIN 02244839 · $0.3032
Sandoz Sertraline · DIN 02245160 · $0.3032
Sertraline · DIN 02353539 · $0.3032
Sertraline · DIN 02386089 · $0.3032
Sertraline · DIN 02469634 · $0.3032
Teva-Sertraline · DIN 02240484 · $0.3032
Zoloft · DIN 01962817 · $0.3032
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02402394
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Sertraline · DIN 02488442 · 50mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Sertraline · DIN 02488442
Manufacturer: Nora Pharma; listing date 2021-03-29
Health Canada: Marketed since 2019-09-04 · brand NRA-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 50 MG · company Nora pharma inc · schedule Prescription
NRA-Sertraline: Formulary list price $0.3032/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3032 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97853 · Verify on the e-Formulary ↗ (DIN 02488442)
Source record
DIN 02488442: NRA-Sertraline
Raw flags: sec3=Y
Item: 281604060; group id 470; item number 1182; lccId None; manufacturer id NRA
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.3032; ministry $0.3032
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02488442
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97853
Interchangeable products
AG-Sertraline · DIN 02477890 · $0.3032
Apo-Sertraline · DIN 02238281 · $0.3032
Auro-Sertraline · DIN 02390914 · $0.3032
Co Sertraline · DIN 02287404 · $0.3032
Jamp-Sertraline · DIN 02357151 · $0.3032
M-Sertraline · DIN 02530945 · $0.3032
Mar-Sertraline · DIN 02399423 · $0.3032
Mint-Sertraline · DIN 02402394 · $0.3032
PMS-Sertraline · DIN 02244839 · $0.3032
Sandoz Sertraline · DIN 02245160 · $0.3032
Sertraline · DIN 02353539 · $0.3032
Sertraline · DIN 02386089 · $0.3032
Sertraline · DIN 02469634 · $0.3032
Teva-Sertraline · DIN 02240484 · $0.3032
Zoloft · DIN 01962817 · $0.3032
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02488442
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Sertraline · DIN 02244839 · 50mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Sertraline · DIN 02244839
Manufacturer: Pharmascience Inc.; listing date 2003-01-30
Health Canada: Marketed since 2002-01-30 · brand PMS-SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 50 MG · company Pharmascience inc · schedule Prescription
PMS-Sertraline: Formulary list price $0.3032/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3032 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68829 · Verify on the e-Formulary ↗ (DIN 02244839)
Source record
DIN 02244839: PMS-Sertraline
Raw flags: sec3=Y
Item: 281604060; group id 470; item number 1182; lccId None; manufacturer id PMS
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.3032; ministry $0.3032
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244839
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68829
Interchangeable products
AG-Sertraline · DIN 02477890 · $0.3032
Apo-Sertraline · DIN 02238281 · $0.3032
Auro-Sertraline · DIN 02390914 · $0.3032
Co Sertraline · DIN 02287404 · $0.3032
Jamp-Sertraline · DIN 02357151 · $0.3032
M-Sertraline · DIN 02530945 · $0.3032
Mar-Sertraline · DIN 02399423 · $0.3032
Mint-Sertraline · DIN 02402394 · $0.3032
NRA-Sertraline · DIN 02488442 · $0.3032
Sandoz Sertraline · DIN 02245160 · $0.3032
Sertraline · DIN 02353539 · $0.3032
Sertraline · DIN 02386089 · $0.3032
Sertraline · DIN 02469634 · $0.3032
Teva-Sertraline · DIN 02240484 · $0.3032
Zoloft · DIN 01962817 · $0.3032
Shortage status: resolved shortage (ended 2019-12-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244839
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sertraline · DIN 02353539 · 50mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sertraline · DIN 02353539
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2022-06-21 · brand SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 50 MG · company Sanis health inc · schedule Prescription
Sertraline: Formulary list price $0.3032/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3032 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83875 · Verify on the e-Formulary ↗ (DIN 02353539)
Source record
DIN 02353539: Sertraline
Raw flags: sec3=Y
Item: 281604060; group id 470; item number 1182; lccId None; manufacturer id SAI
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.3032; ministry $0.3032
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02353539
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83875
Interchangeable products
AG-Sertraline · DIN 02477890 · $0.3032
Apo-Sertraline · DIN 02238281 · $0.3032
Auro-Sertraline · DIN 02390914 · $0.3032
Co Sertraline · DIN 02287404 · $0.3032
Jamp-Sertraline · DIN 02357151 · $0.3032
M-Sertraline · DIN 02530945 · $0.3032
Mar-Sertraline · DIN 02399423 · $0.3032
Mint-Sertraline · DIN 02402394 · $0.3032
NRA-Sertraline · DIN 02488442 · $0.3032
PMS-Sertraline · DIN 02244839 · $0.3032
Sandoz Sertraline · DIN 02245160 · $0.3032
Sertraline · DIN 02386089 · $0.3032
Sertraline · DIN 02469634 · $0.3032
Teva-Sertraline · DIN 02240484 · $0.3032
Zoloft · DIN 01962817 · $0.3032
Shortage status: resolved shortage (ended 2024-06-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02353539
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sertraline · DIN 02386089 · 50mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sertraline · DIN 02386089
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2019-04-05 · brand SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 50 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Sertraline: Formulary list price $0.3032/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3032 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87167 · Verify on the e-Formulary ↗ (DIN 02386089)
Source record
DIN 02386089: Sertraline
Raw flags: sec3=Y
Item: 281604060; group id 470; item number 1182; lccId None; manufacturer id SIV
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.3032; ministry $0.3032
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386089
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87167
Interchangeable products
AG-Sertraline · DIN 02477890 · $0.3032
Apo-Sertraline · DIN 02238281 · $0.3032
Auro-Sertraline · DIN 02390914 · $0.3032
Co Sertraline · DIN 02287404 · $0.3032
Jamp-Sertraline · DIN 02357151 · $0.3032
M-Sertraline · DIN 02530945 · $0.3032
Mar-Sertraline · DIN 02399423 · $0.3032
Mint-Sertraline · DIN 02402394 · $0.3032
NRA-Sertraline · DIN 02488442 · $0.3032
PMS-Sertraline · DIN 02244839 · $0.3032
Sandoz Sertraline · DIN 02245160 · $0.3032
Sertraline · DIN 02353539 · $0.3032
Sertraline · DIN 02469634 · $0.3032
Teva-Sertraline · DIN 02240484 · $0.3032
Zoloft · DIN 01962817 · $0.3032
Shortage status: resolved shortage (ended 2019-04-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02386089
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sertraline · DIN 02469634 · 50mg · capsule
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sertraline · DIN 02469634
Manufacturer: Jamp Pharma Corporation; listing date 2018-02-28
Health Canada: Marketed since 2018-01-17 · brand SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 50 MG · company Jamp pharma corporation · schedule Prescription
Sertraline: Formulary list price $0.3032/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3032 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95843 · Verify on the e-Formulary ↗ (DIN 02469634)
Source record
DIN 02469634: Sertraline
Raw flags: sec3=Y
Item: 281604060; group id 470; item number 1182; lccId None; manufacturer id JPC
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.3032; ministry $0.3032
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02469634
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95843
Interchangeable products
AG-Sertraline · DIN 02477890 · $0.3032
Apo-Sertraline · DIN 02238281 · $0.3032
Auro-Sertraline · DIN 02390914 · $0.3032
Co Sertraline · DIN 02287404 · $0.3032
Jamp-Sertraline · DIN 02357151 · $0.3032
M-Sertraline · DIN 02530945 · $0.3032
Mar-Sertraline · DIN 02399423 · $0.3032
Mint-Sertraline · DIN 02402394 · $0.3032
NRA-Sertraline · DIN 02488442 · $0.3032
PMS-Sertraline · DIN 02244839 · $0.3032
Sandoz Sertraline · DIN 02245160 · $0.3032
Sertraline · DIN 02353539 · $0.3032
Sertraline · DIN 02386089 · $0.3032
Teva-Sertraline · DIN 02240484 · $0.3032
Zoloft · DIN 01962817 · $0.3032
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02469634
Shortage record checked 2026-09-13T08:10:21.292534+00:00